(12) United States Patent (10) Patent No.: US 6,743,784 B2 Ruenitz (45) Date of Patent: Jun
USOO6743784B2 (12) United States Patent (10) Patent No.: US 6,743,784 B2 Ruenitz (45) Date of Patent: Jun. 1, 2004 (54) ESTROGEN MIMETICS LACKING Emmens, “Halogen-Substituted Oestrogens Related to REPRODUCTIVE TRACT EFFECTS Triphenylethylene,” J. Endocrinol., Dodds, E.C.; Williams, P.C.; eds., 5:170–173 (1946–48). (75) Inventor: Peter C. Ruenitz, Athens, GA (US) Francis et al., “The Development of Diphosphonates as Significant Health Care Products,” J. Chem. Educ., (73) Assignee: The University of Georgia Research 55(12):760–766 (1978). Foundation, Inc., Athens, GA (US) Frolik et al., “Time-Dependent Changes in Biochemical Bone Markers and Serum Cholesterol in Ovariectomized * ) Notice: Subject to anyy disclaimer, the term of this Rats: Effects of Raloxifene HCI, Tamoxifen, Estrogen, and patent is extended or adjusted under 35 Alendronate.” Bone, 18(6): 621-627 (1996). U.S.C. 154(b) by 0 days. Frost, “Bone Histomorphometry: Analysis of Trabecular Bone Dynamics.” Bone Histomorphometry. Techniques and (21) Appl. No.: 09/981,617 Interpretation, Recker, ed., Boca Raton, FL, CRC Press, pp. 109-131 (1983). (22) Filed: Oct. 15, 2001 Fujisaki et al., “Osteotropic Drug Delivery System (ODDS) (65) Prior Publication Data Based on Bisphosphonic Prodrug. V. Biological Diposition and Targeting Characteristics of Osteotropic Estradiol, US 2002/0045664 A1 Apr. 18, 2002 Biol. Pharm. Bull., 20011): 1183–1187 (1997). Hyder et al., “Estrogen Action in Target Cells: Selective Related U.S. Application Data Requirements for Activation of Different Hormone (63) Continuation of application No. 09/363.911, filed on Jul. 28, Response Elements,” Mol. Cell. Endocrinol., 112: 35–43 1999, now Pat.
[Show full text]